SRx Health Solutions (SRXH)
XASE:SRXH
Want to see SRXH full AI Analyst Report?
Top Page
SRx Health Solutions
(NYSE MKT:SRXH)
Select Model
Select Model
Rating:45Neutral
Price Target:
$0.12
▼(-49.58% Downside)
Action:Reiterated
Date:06/19/26
The score is mainly held down by weak financial performance (large losses, high leverage, and negative recent cash flow) and a technically weak price trend below major moving averages. Corporate events provide some upside optionality via the strategic pivot and acquisitions, but valuation signals offer limited support given the non-meaningful P/E and lack of dividend yield.
Positive Factors
Strategic pivot to AI-driven platform & digital-asset treasury
The acquisition and AI-driven platform reposition the company from a niche specialty-pharmacy operator toward a diversified capital-allocation platform. Over months, this can create new recurring fee streams and scale benefits from asset-management and analytics capabilities if execution preserves operational focus.
Negative Factors
Extremely high leverage and thin equity base
Very high leverage and a historically thin or negative equity base materially constrain financial flexibility. Over months, elevated debt amplifies refinancing, covenant and dilution risk, limiting the firm's ability to invest in the new strategy without securing additional capital under potentially adverse terms.
Read all positive and negative factors
Positive Factors
Negative Factors
Strategic pivot to AI-driven platform & digital-asset treasury
The acquisition and AI-driven platform reposition the company from a niche specialty-pharmacy operator toward a diversified capital-allocation platform. Over months, this can create new recurring fee streams and scale benefits from asset-management and analytics capabilities if execution preserves operational focus.
Read all positive factors
SRx Health Solutions (SRXH) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$73.49M
Dividend YieldN/A
Average Volume (3M)695.52K
Price to Earnings (P/E)―
Beta (1Y)0.11
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees11
SectorConsumer Defensive
Sector Strength42
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)-213365.32
Shares Outstanding590,254,760
10 Day Avg. Volume504,141
30 Day Avg. Volume695,518
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)16.44
Price to Sales (P/S)1.02
P/FCF Ratio-0.82
Enterprise Value/Market Cap0.12
Enterprise Value/Revenue-0.29
Enterprise Value/Gross Profit-1.08
Enterprise Value/Ebitda-0.20
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.32
Revenue Forecast (FY)$95.00M
SRx Health Solutions Business Overview & Revenue Model
Company Description
SRx Health Solutions Inc. functions as a unified Canadian enterprise providing healthcare services, specifically within the specialized medical sector. The company furnishes a complete range of personalized and interconnected specialty healthcare ...
How the Company Makes Money
SRx Health Solutions primarily generates revenue through pharmacy and patient-support related healthcare services. Key revenue streams generally include (i) dispensing and distribution of prescription medications through its pharmacy operations, w...
SRx Health Solutions Earnings Call Summary
Earnings Call Date:Mar 27, 2025
(Q4-2024)
| % Change Since: |
Next Earnings Date:May 20, 2027
Earnings Call Sentiment Positive
The earnings call highlighted significant improvements in profitability measures, including gross profit margins, net loss, and EBITDA. Revenue growth, particularly in the fourth quarter and international markets, was strong. However, there were challenges such as a decline in annual net revenues and ongoing EBITDA losses. Overall, the company's strategic pivots and financial health improvements contributed to a positive outlook.Positive Updates
Improved Gross Profit Margin
The company reported a gross profit margin of 37% for the full year, representing an increase of over 600 basis points.
Negative Updates
Decline in Annual Net Revenues
Annual net revenues were down 9% due to strategic exits from non-core sales channels and the closure of an unprofitable direct-to-consumer business.
Read all updates
Q4-2024 Updates
Positive
Negative
Improved Gross Profit Margin
The company reported a gross profit margin of 37% for the full year, representing an increase of over 600 basis points.
Read all positive updates
Company Guidance
In the fourth quarter of 2024, Better Choice Company reported notable financial achievements and strategic advancements. The company delivered a gross profit margin of 37%, improving by over 600 basis points year-over-year, and adjusted EBITDA loss was reduced by 78% to approximately $1.9 million on annual net revenues of $35 million. The company experienced a 26% increase in fourth-quarter revenue, driven by 32% growth on platforms like Amazon and Chewy, and 18% international growth. Key operational improvements included a 22% reduction in SG&A expenses and a more than 40% reduction in inventory, leading to a working capital position of $7.9 million. Additionally, Better Choice successfully negotiated a $6.2 million gain from extinguishing debt and accounts payable. The company's focus on e-commerce channels is expected to continue propelling growth into 2025, as evidenced by the profitability improvements and strategic exits from non-core sales channels. Looking forward, Better Choice is poised for expanded growth through its acquisition of SRx Health Solutions, which is anticipated to close in April, further solidifying its position as a leader in the pet health and wellness sector.SRx Health Solutions Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
22
Negative
Cash Flow
18
Very Negative
| Breakdown | TTM | Sep 2025 | Dec 2024 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | -30.49M | 6.53M | 50.30M | 118.94M | 92.63M | 58.63M |
| Gross Profit | -8.22M | 1.50M | 18.49M | 23.61M | 13.31M | 17.47M |
| EBITDA | -44.99M | -11.50M | 629.88K | -7.05M | -539.40K | 10.58M |
| Net Income | -51.41M | -45.01M | -241.60K | -11.14M | -2.45M | 3.80M |
Balance Sheet | ||||||
| Total Assets | 43.36M | 8.40M | 21.44M | 64.51M | 34.79M | 98.67M |
| Cash, Cash Equivalents and Short-Term Investments | 26.07M | 1.31M | 4.16M | 2.07M | 1.66M | 36.89M |
| Total Debt | 22.62M | 4.47M | 2.02M | 39.38M | 17.85M | 13.16M |
| Total Liabilities | 25.08M | 8.00M | 88.88M | 70.80M | 33.86M | 24.91M |
| Stockholders Equity | 18.29M | 407.00K | 10.30M | -6.29M | 927.48K | 73.76M |
Cash Flow | ||||||
| Free Cash Flow | 4.06M | -8.14M | -5.97M | 1.58M | 3.13M | -15.56M |
| Operating Cash Flow | 4.06M | -8.14M | -5.91M | 2.85M | -27.62M | -15.11M |
| Investing Cash Flow | -25.78M | 5.91M | -3.06M | -19.78M | -266.04K | -449.89K |
| Financing Cash Flow | 53.29M | 12.17M | 7.08M | 16.43M | 3.80M | 47.36M |
SRx Health Solutions Technical Analysis
Negative
0.24
Price Trends
0.13
Negative
0.13
Negative
0.22
Negative
Market Momentum
<0.01
Negative
46.02
Neutral
48.54
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SRXH, the sentiment is Negative. The current price of 0.24 is above the 20-day moving average (MA) of 0.13, above the 50-day MA of 0.13, and above the 200-day MA of 0.22, indicating a bearish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 46.02 is Neutral, neither overbought nor oversold. The STOCH value of 48.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SRXH.
SRx Health Solutions Risk Analysis
SRx Health Solutions disclosed 96 risk factors in its most recent earnings report. SRx Health Solutions reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
SRx Health Solutions Peers Comparison
UnderperformOutperform
Sector (62)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | $3.53B | 14.21 | 29.87% | 4.80% | -2.08% | -67.52% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
59 Neutral | $6.26B | 14.77 | 7.88% | 1.56% | 8.91% | 129.84% | |
45 Neutral | $73.49M | ― | 875.03% | ― | ― | ― | |
45 Neutral | $62.27M | -1.58 | -99.47% | ― | ― | ― |
* Consumer Defensive Sector Average
SRXH
SRx Health Solutions
0.12
-0.44
-77.94%
GRFS
Grifols SA
7.40
-1.25
-14.45%
SCLX
Scilex Holding Company
7.47
4.41
144.36%
OGN
Organon
13.43
3.77
38.97%
CTOR
Citius Oncology
0.67
-1.96
-74.56%
MIRA
MIRA Pharmaceuticals, Inc.
0.95
-0.27
-21.97%
SRx Health Solutions Corporate Events
Business Operations and StrategyM&A TransactionsRegulatory Filings and Compliance
SRx Health Rebrands, Completes Crypto Share Exchange Pivot
Positive
Jun 18, 2026
On June 18, 2026, SRx Health Solutions completed its previously announced share exchange transaction with EMJ Crypto Technologies and CCC Crypto, acquiring full ownership of both entities and associated IP assets. In exchange, the company issued h...
Business Operations and StrategyM&A Transactions
SRx Health Shifts Capital Toward AI and Space Investments
Positive
Apr 22, 2026
On April 22, 2026, SRx Health Solutions announced that its wholly owned pet-focused subsidiary, Halo, Purely for Pets, invested more than 10% of the company’s investable capital in Astro Investment XVII, an affiliate of Astro Capital structu...
Business Operations and StrategyFinancial DisclosuresM&A TransactionsRegulatory Filings and Compliance
SRx Health Updates Shareholders on EMJX Merger Progress
Positive
Apr 17, 2026
On April 17, 2026, SRx Health Solutions and EMJ Crypto Technologies released a shareholder letter detailing operational progress and the status of their proposed merger, which was first announced in December 2025. EMJX highlighted strong early per...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.